Skip Navigation


Annals of Oncology Advance Access originally published online on August 22, 2007
Annals of Oncology 2007 18(10):1632-1640; doi:10.1093/annonc/mdm268
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/10/1632    most recent
mdm268v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Colleoni, M.
Right arrow Articles by Viale, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colleoni, M.
Right arrow Articles by Viale, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast cancer

Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer

M. Colleoni1,*, N. Rotmensz2, P. Maisonneuve3, A. Sonzogni4, G. Pruneri4, C. Casadio4, A. Luini5, P. Veronesi5,6, M. Intra5, V. Galimberti5, R. Torrisi1, S. Andrighetto4, R. Ghisini1, A. Goldhirsch1 and G. Viale4,6

1 Research Unit in Medical Senology at the Department of Medicine
2 Unit of Quality Control
3 Division of Epidemiology and Biostatistics
4 Division of Pathology and Laboratory Medicine
5 Division of Senology, European Institute of Oncology
6 University of Milan School of Medicine, Milan, Italy

* Correspondence to: Marco Colleoni MD, Research Unit in Medical Senology at the Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy. Tel: +39–02–57489439; Fax: +39–02–574829212; E-mail address: marco.colleoni{at}ieo.it

Background: The clinical relevance of the degree of peritumoral vascular invasion (PVI) in patients with no or limited involvement of the axillary nodes is unknown.

Materials and methods: 2606 consecutive patients with pT1-3, pN0 (1586)-1a (1020) and M0, operated and counseled for medical therapy from 1/2000 to 12/2002, were prospectively classified according to the degree of PVI: absent (2017, 77.4%), focal (368, 14.1%), moderate (51, 2.0%) and extensive (170, 6.5%).

Results: Patients with extensive PVI were more likely to be younger, to have larger tumors, high tumor grade, axillary-positive nodes, high Ki-67 expression and HER2/neu over-expression compared with patients having less PVI (P for trend, <0.0001). In patients with node-negative disease a statistically significant difference in disease-free survival (DFS), risk of distant metastases and overall survival (OS) was observed at the multivariate analysis for extensive PVI versus no PVI (hazard ratios: 2.11, 95% CI, 1.02 to 4.34, P = 0.04 for DFS; 4.51, 95% CI, 1.96 to 10.4, P< 0.001 for distant metastases; 3.55, 95% CI, 1.24 to 10.1, P = 0.02 for OS).

Conclusions: The extent of vascular invasion should be considered in the therapeutic algorithm in order to properly select targeted adjuvant treatment.

Key words: peritumoral vascular invasion, breast cancer, prognostic factor

Received for publication January 19, 2007. Revision received March 9, 2007. Accepted for publication April 30, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2007 18: 1589. [Extract] [Full Text]  





Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.